SNU-484 Xenograft Model Service for Gastric Cancer

The SNU-484 xenograft model provides a robust preclinical platform for evaluating therapeutic efficacy against gastric adenocarcinoma, leveraging a well-characterized cell line with documented in vivo tumorigenicity and drug responsiveness. Alfa Cytology delivers comprehensive SNU-484 xenograft model services, from cell line expansion and quality-controlled inoculation to longitudinal tumor monitoring and endpoint analysis, ensuring reproducible data to advance your gastric cancer drug development pipeline.

Overview of SNU-484 Xenograft Model for Gastric Cancer

The SNU-484 cell line was established from a gastric adenocarcinoma specimen obtained from a 53-year-old male patient and exhibits epithelial morphology with monolayer growth characteristics. This cell line carries a documented TP53 mutation (exon 8, codon 226, GGA to GAA, Gly to Glu) and has been extensively utilized in preclinical oncology research, demonstrating reliable tumorigenicity in immunodeficient mouse models. In xenograft studies, SNU-484 tumors show consistent subcutaneous growth with measurable responses to standard cytotoxic agents such as paclitaxel, achieving tumor regression endpoints that correlate with hollow fiber assay data. The model is particularly valued for its intermediate drug sensitivity profile, making it suitable for evaluating novel targeted agents, combination regimens, and biomarker-driven therapeutic strategies in gastric cancer.

SNU-484 xenografts are typically established in NOD/SCID or nude mouse strains via subcutaneous flank injection, with tumor volumes calculated using the standard ellipsoid formula (V = 1/2 x a x b^2). The model supports both single-agent and combination therapy studies, with documented applications in evaluating HER inhibitors, ATR inhibitors, and cytotoxic chemotherapy. Tumor growth kinetics are generally consistent across male and female hosts, and the cell line's well-defined molecular background---including wild-type KRAS and mutant TP53 status---provides a predictable framework for mechanism-of-action studies and pharmacodynamic assessments in gastric cancer preclinical development.

Figure 1. Tumorigenesis in the BALB/c mouse. (Yoon, Seon-Jin, et al., 2020)

Cell Line Information: SNU-484

SNU-484 is a human gastric adenocarcinoma cell line established as part of the Seoul National University (SNU) cell line collection. The following table summarizes the key characteristics and culture parameters of this cell line.

Our Services

Alfa Cytology offers end-to-end SNU-484 xenograft model services tailored to your preclinical research objectives, encompassing cell line resuscitation and expansion, immunodeficient mouse model establishment, randomized treatment group allocation, longitudinal tumor volume monitoring, and comprehensive endpoint histopathological analysis. Our experienced team ensures rigorous quality control at every stage---from mycoplasma testing and STR authentication to standardized tumor measurement protocols---delivering high-quality, reproducible datasets that support IND-enabling studies and translational oncology programs for gastric cancer therapeutics.

Workflow of SNU-484 Xenograft Model Construction

The construction of SNU-484 xenograft models follows a standardized, multi-step protocol optimized for consistent tumor engraftment and reliable therapeutic response assessment. Each phase is executed under strict quality control to ensure data reproducibility and regulatory compliance.

1. Cell Line Preparation and Quality Control. SNU-484 cells are recovered from cryogenic storage and expanded in RPMI-1640 medium supplemented with 10% FBS under standard incubation conditions (37 degrees C, 5% CO2). Prior to inoculation, cells undergo mycoplasma testing, STR authentication, and viability assessment to confirm identity and functional integrity.
2. Recipient Mouse Selection and Preparation. Immunodeficient NOD/SCID or athymic nude mice (typically 6-8 weeks old) are acclimatized under pathogen-free conditions. Baseline body weights and health status are recorded to ensure uniform cohorts.
3. Tumor Cell Inoculation. SNU-484 cells are harvested at logarithmic growth phase, washed, and resuspended in serum-free RPMI-1640. The cell suspension (typically 1x10^7 cells in 100 uL) is mixed 1:1 with Matrigel basement membrane matrix and injected subcutaneously into the flank region of recipient mice using aseptic technique.
4. Tumor Establishment and Monitoring. Tumor growth is monitored twice weekly by caliper measurement. Tumor volume is calculated using the formula V = 1/2 x a x b^2, where a and b represent the longest and shortest diameters, respectively. Mice are randomized into treatment groups once tumors reach approximately 100 mm3.
5. Treatment Administration and Response Evaluation. Test compounds or vehicle controls are administered according to the study design (oral gavage, intraperitoneal, or intravenous). Tumor volumes and body weights are recorded at defined intervals. Treatment efficacy is quantified using percent treated/control (%T/C) ratios, with tumor regression defined as negative %T/C values relative to baseline.
6. Endpoint Analysis and Sample Collection. At study termination, tumors are excised, weighed, and processed for downstream analyses including histopathology (H&E staining), immunohistochemistry (IHC), biomarker expression profiling, and pharmacodynamic assessments. Serum and plasma samples may be collected for PK/PD correlation studies.

Figure 2. SNU-484 xenograft model construction workflow.

Case Study-SNU-484 Xenograft Model Development

In a representative preclinical development program, SNU-484 xenografts were successfully established in NOD/SCID mice with a 100% tumor take rate, achieving measurable palpable tumors within two weeks post-inoculation. The model demonstrated robust sensitivity to paclitaxel treatment, with treated cohorts exhibiting significant tumor regression compared to vehicle controls, validating the model's predictive value for cytotoxic agent screening. Pharmacodynamic analysis revealed consistent modulation of proliferation and apoptosis markers in responsive tumors, supporting the utility of this platform for evaluating novel therapeutic candidates. Tumor growth kinetics remained stable across replicate studies, and the intermediate drug sensitivity profile of SNU-484 provided a discriminative window for detecting both potent single-agent activity and synergistic combination effects. These data underscore the reliability of the SNU-484 xenograft model as a cornerstone for gastric cancer preclinical pharmacology and translational drug development programs.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific rigor with operational excellence to deliver SNU-484 xenograft model services that meet the highest standards of preclinical oncology research. Our integrated platform ensures seamless execution from study design to data delivery.

• Rigorous cell line quality control including STR authentication, mycoplasma testing, and viability verification prior to every inoculation.
• Standardized xenograft protocols optimized for SNU-484 tumorigenicity, ensuring consistent tumor take rates and growth kinetics across studies.
• Comprehensive in-life monitoring with calibrated caliper measurements, electronic data capture, and real-time tumor volume tracking.
• Flexible study designs accommodating single-agent, combination, dose-escalation, and biomarker-driven pharmacodynamic endpoints.
• Expert histopathology and molecular analysis capabilities including H&E, IHC, and multi-omics sample processing for mechanistic insights.
• Dedicated project management with transparent reporting timelines and regulatory-compliant documentation to support IND submissions.

Contact Us

Accelerate your gastric cancer drug development program with Alfa Cytology's validated SNU-484 xenograft model services. Our team is ready to design customized preclinical studies that align with your therapeutic targets and regulatory milestones. Contact us today to discuss your project requirements, receive a detailed study proposal, and partner with a CRO committed to delivering reproducible, publication-ready data.

Reach out to our scientific team to explore how the SNU-484 xenograft model can advance your preclinical oncology portfolio. We look forward to supporting your research from lead optimization through IND-enabling studies. Please reach out to us today via our inquiry form or email to learn more about our SNU-484 Xenograft Model services.

For research use only. Not intended for any clinical use.